V. Rethwisch

Continued Treatment with An Outpatient Maintenance Schedule of Decitabine in Older AML Patients Ineligible for Induction Chemotherapy: Results of the 00331 Phase II Multicenter Trial

H. Döhner, A. Ganser, C. Schmoor, 2008 .

Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.

R. Hofheinz, J. Hartmann, J. Stoehlmacher, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.

C. Bokemeyer, S. Hollerbach, R. Hofheinz, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The feasibility of triple-drug chemotherapy combination in older adult patients with oesophagogastric cancer: a randomised trial of the Arbeitsgemeinschaft Internistische Onkologie (FLOT65+).

C. Bokemeyer, S. Hollerbach, R. Hofheinz, 2013, European journal of cancer.

A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy

K. Döhner, H. Döhner, A. Ganser, 2012, Haematologica.

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial

M. Egger, V. Heinemann, J. Trojan, 2019, The Lancet.

Modified FOLFOX in combination with docetaxel for patients with metastatic adenocarcinoma of the stomach or gastroesophageal junction: A multicenter phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)

R. Hofheinz, J. Hartmann, J. Stoehlmacher, 2007 .

Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)†.

M. Rezai, T. Fehm, T. Kühn, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.